Variable | Total, N | No complication group, N (%) | Complication group, N (%) | p |
---|---|---|---|---|
Number of Patients | 1081 | 1022 (94.5) | 59 (5.5) | Â |
Location | Â | Â | Â | 0.032 |
 Right | 514 | 484 (94.2) | 30 (5.8) |  |
 Left | 499 | 478 (95.8) | 21 (4.2) |  |
 Bilateral | 68 | 60 (88.2) | 8 (11.8) |  |
Histopathology | Â | Â | Â | 0.939 |
 Invasive cancer | 841 | 794 (94.4) | 47 (5.6) |  |
 DCIS | 199 | 189 (95.0) | 10 (5.0) |  |
 Other | 41 | 39 (95.1) | 2 (4.9) |  |
Nuclear grade | Â | Â | Â | 0.966 |
 Low | 153 | 144 (94.1) | 9 (5.9) |  |
 Intermediate | 663 | 627 (94.6) | 36 (5.4) |  |
 High | 265 | 251 (94.7) | 14 (5.3) |  |
LVI | Â | Â | Â | 0.001 |
 Yes | 285 | 258 (90.5) | 27 (9.5) |  |
 No | 796 | 764 (96.0) | 32 (4.0) |  |
Pathologic T | Â | Â | Â | 0.118 |
 Tis & pCR | 212 | 207 (97.6) | 5 (2.4) |  |
 T1 | 514 | 484 (94.2) | 30 (5.8) |  |
 T2 | 299 | 280 (93.6) | 19 (6.4) |  |
 ≥ T3 | 56 | 51 (91.1) | 5 (8.9) |  |
Pathologic N |  |  |  | < 0.001 |
 N0 | 795 | 768 (96.6) | 27 (3.4) |  |
 N1 | 227 | 208 (91.6) | 19 (8.4) |  |
 N2 | 42 | 33 (78.6) | 9 (21.4) |  |
 N3 | 17 | 13 (76.5) | 4 (23.5) |  |
Pathologic prognostic stage | Â | Â | Â | 0.017 |
 0 & NRT | 207 | 199 (96.1) | 8 (3.9) |  |
 I | 456 | 431 (94.5) | 25 (5.5) |  |
 II | 342 | 326 (95.3) | 16 (4.7) |  |
 III | 76 | 66 (86.8) | 10 (13.2) |  |
ER | Â | Â | Â | 0.445 |
 Positive | 895 | 844 (94.3) | 51 (5.7) |  |
 Negative | 186 | 178 (95.7) | 8 (4.3) |  |
PR | Â | Â | Â | 0.192 |
 Positive | 842 | 792 (94.1) | 50 (5.9) |  |
 Negative | 239 | 230 (96.2) | 9 (3.8) |  |
C-erbB-2 | Â | Â | Â | 0.586 |
 Positive | 296 | 280 (94.6) | 16 (5.4) |  |
 Negative | 664 | 630 (94.9) | 34 (5.1) |  |
 Unknown | 121 | 112 (92.6) | 9 (7.4) |  |
Subtype | Â | Â | Â | 0.880 |
 HR (+) | 900 | 849 (94.3) | 51 (5.7) |  |
 HR(−) C-erbB-2(+) | 121 | 116 (95.9) | 5 (4.1) |  |
 HR(−) C-erbB-2(−) | 56 | 53 (94.6) | 3 (5.4) |  |
 Unknown | 4 | 4 (100.0) | 0 (0.0) |  |